- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT06913023
Semaglutídeo para a prevenção do diabetes mellitus pós-transplante (SPOT-DM)
The study aims to determine the short-term efficacy, mechanisms and safety of 24 weeks of semaglutide therapy in 37 KTR at risk of post-transplant diabetes mellitus (PTDM).
Visão geral do estudo
Status
Condições
Descrição detalhada
A kidney transplant is the best treatment for people living with kidney failure as it allows people to live longer with a better quality of life. However, one in four kidney transplant recipients will develop diabetes after transplant. This is largely due to the medications that must be used to prevent rejection of the transplant. Kidney transplant recipients who get diabetes after transplant are up to three times more likely to have heart disease and die prematurely. To date, there are no treatments to prevent the development of diabetes after kidney transplant. Semaglutide is a drug that is commonly used to treat diabetes and obesity. The investigators believe that semaglutide is a safe and effective drug which can prevent the development of diabetes in kidney transplant recipients. Therefore, the investigators are conducting a study where kidney transplant recipients who are at increased risk of developing diabetes after transplant will receive semaglutide for 24 weeks after their transplant. The study will determine whether semaglutide is effective in decreasing blood sugar levels and the rate of diabetes. The investigators will also study other important markers of health including body weight and cholesterol levels as well as liver, kidney and heart function. Diabetes after transplant is a common problem, and preventing it is extremely important to allowing kidney transplant recipients to live longer and better lives. The results of this study will allow the investigators to determine if semaglutide is a safe and effective option for the prevention of diabetes in kidney transplant recipients.
Tipo de estudo
Inscrição (Estimado)
Estágio
- Fase 2
- Fase 3
Contactos e Locais
Contato de estudo
- Nome: Cheng Xu
- Número de telefone: 8508 416-340-4800
- E-mail: cheng.xu@uhn.ca
Locais de estudo
-
-
British Columbia
-
Vancouver, British Columbia, Canadá, V6Z 1Y6
- St. Paul's Hospital
-
Contato:
- Vikas S Srinivasan, MD PhD FRCPC
- Número de telefone: 604-806-8970
- E-mail: vikas.sridhar@phc.ca
-
-
Ontario
-
Toronto, Ontario, Canadá, M5G 2N2
- Toronto General Hospital
-
Contato:
- Cheng Xu
- Número de telefone: 8508 416-340-4800
- E-mail: cheng.xu@uhn.ca
-
Investigador principal:
- Sunita Singh, MD MSc FRCPC
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
-
Signed and dated written informed consent.
-
Adult (≥18 years) recipients of a living or deceased donor kidney transplant
-
Between 4- and 12-weeks post kidney transplant
-
Stable kidney function defined as an eGFR > 30 ml/min/1.73m2 (CKD-EPI)
-
At risk for PTDM at the time of transplant based on the following criteria:
- BMI ≥ 25 kg/m2, or
- Fasting plasma glucose 6.1-6.9 mmol/L (impaired fasting glucose), or
- 2hr OGTT plasma glucose 7.8-11.0 (impaired glucose tolerance), or
- HbA1C 5.5-6.4% (at risk for DM or prediabetes).
Exclusion Criteria:
- Established diagnosis of type 1 or type 2 DM as per Diabetes Canada (including the need for glucose-lowering therapy for hyperglycemia at the time of screening)
- Kidney-Pancreas transplant recipient
- Acute coronary syndrome, transient ischemic attack or stroke within 30 days prior to screening
- History of pancreatitis
- Personal or family history of medullary thyroid cancer or MEN2B
- Women who are pregnant, nursing or plan on becoming pregnant whilst in the trial
- Use of GLP1RA in the 30 days prior to screening
- Contraindication to MRI (applicable only to those undergoing the optional MRI assessments)
- With known or suspected hypersensitivity to semaglutide or related products
- Patient not able to understand and comply with study requirements, based on Investigator's judgment.
- Any other clinical condition that, based on Investigator's judgement, would jeopardize patient safety during trial participation or would affect the study outcom
- History of glucose-galactose malabsorption syndrome
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: N / D
- Modelo Intervencional: Atribuição de grupo único
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Semaglutide
Patients will be up-titrated as tolerated starting at 0.25 mg subcutaneous semaglutide once weekly for 4 weeks, followed by 0.5 mg, 1.0 mg, and 1.7 mg semaglutide for 4 weeks each, and then 2.4 mg subcutaneous semaglutide once weekly for 8 weeks. Semaglutide can be down-titrated by the investigator to lower doses or up-titrated at slower rates if not tolerated by the participant. |
Subcutaneous semaglutide 0.25mg for 4 weeks. Subcutaneous semaglutide 0.5mg for 4 weeks. Subcutaneous semaglutide 1.0 mg for 4 weeks. Subcutaneous semaglutide 1.7 mg for 4 weeks Subcutaneous semaglutide 2.4 mg for 8 weeks |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
2-hour OGTT
Prazo: 24 weeks
|
The primary outcome of this study is the change in plasma glucose at 120 minutes following a 75g oral glucose challenge (2-hour OGTT) at 24 weeks. The 2-hour OGTT was selected as the primarily outcome in this study for the following reasons: 1) In selecting a surrogate outcome for PTDM in KTR, there are limitations to HbA1c and fasting glucose in this population; 2) The 2-hour OGTT is the recommended test for the diagnosis of PTDM in KTR and 3) The use of OGTT has been used in other PTDM prevention studies. |
24 weeks
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Pressão arterial sistólica
Prazo: 24 semanas
|
24 semanas
|
|
|
Mudança no peso corporal
Prazo: 24 semanas
|
24 semanas
|
|
|
Mudança na circunferência da cintura
Prazo: 24 semanas
|
24 semanas
|
|
|
Mudança na HbA1c
Prazo: 24 semanas
|
24 semanas
|
|
|
Mudança na glicose no sangue em jejum
Prazo: 24 semanas
|
24 semanas
|
|
|
Mudança na insulina sérica
Prazo: 24 semanas
|
24 semanas
|
|
|
Mudança no perfil lipídico em jejum
Prazo: 24 semanas
|
24 semanas
|
|
|
Pressão arterial diastólica
Prazo: 24 semanas
|
24 semanas
|
|
|
Pressão arterial média
Prazo: 24 semanas
|
24 semanas
|
|
|
Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]
Prazo: 24 weeks
|
: The side effects of GLP-1RA have been well described and will be assessed at each study visit. Adverse events include AKI, hypoglycemia, volume depletion, GI intolerance, amputations, pancreatitis, hepatobiliary complications and injection site or allergic reactions, infectious complications (any source), and malignancy. Episodes of biopsy-proven acute rejection (as defined by the Banff criteria), death-censored graft failure (defined as the need for initiation of chronic dialysis or re-transplantation) or death with graft function (defined as death with a functioning allograft) will also be collected. Kidney transplantation assures complete denervation of the transplanted kidney and the renal vasoconstrictive response in the setting of intravascular volume depletion is diminished in KTR. Therefore, frequent monitoring for adverse events has been integrated in our study design, occurring on 10 separate occasions, to capture these adverse events should they occur. |
24 weeks
|
|
Estimated GFR
Prazo: 24 weeks
|
Calculated by CKD-EPI 2021 equation |
24 weeks
|
|
GFR
Prazo: 24 weeks
|
Measured using 24-urine collection for creatinine, standardized per 1.73m2 body surface area. And estimated using CKD-EPI 2021 equation. |
24 weeks
|
|
Albuminuria
Prazo: 24 weeks
|
measuring urine albumin excretion from a 24-hour urine collection |
24 weeks
|
|
Natriuresis
Prazo: 24 weeks
|
Assessed with a 24-hour urine collection for sodium excretion |
24 weeks
|
|
Percentage of body fat
Prazo: 24 weeks
|
Bioimpedance analysis |
24 weeks
|
|
Change in liver enzymes
Prazo: 24 weeks
|
ALT and AST |
24 weeks
|
|
Change in fibrosis level
Prazo: 24 weeks
|
Transient elastography |
24 weeks
|
|
Change in steatosis level
Prazo: 24 weeks
|
Transient elastography |
24 weeks
|
|
Percentage of extracellular fluid
Prazo: 24 weeks
|
Bioimpedance analysis |
24 weeks
|
Outras medidas de resultado
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Change in kidney oxygenation (R2*)
Prazo: 24 weeks
|
Assessed via multiparametric kidney MRI in an optional cohort. |
24 weeks
|
|
Change in kidney fibrosis (ADC)
Prazo: 24 weeks
|
Assessed via multiparametric kidney MRI in an optional cohort. |
24 weeks
|
|
Change in kidney perfusion
Prazo: 24 weeks
|
Assessed via multiparametric kidney MRI in an optional cohort. |
24 weeks
|
|
Change in kidney volume
Prazo: 24 weeks
|
Assessed via multiparametric kidney MRI in an optional cohort. |
24 weeks
|
|
Change in kidney inflammation (T1)
Prazo: 24 weeks
|
Assessed via multiparametric kidney MRI in an optional cohort. |
24 weeks
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Sunita Singh, MD MSc FRCPC, University Health Network, Toronto General Hospital
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Estimado)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- 25-5093
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
produto fabricado e exportado dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .